Strikingly, both transgenic animals and iPSC models of AD indicate that a prominent elevation of OS markers occurs simultaneously with or even prior to the initial AD-related amyloid-β (Aβ) and tau pathology [5–7]. This evidence concerns the gene MAPT and Alzheimer disease.